Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2%

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Currently, 2.6% of the shares of the company are short sold. Based on an average daily volume of 875,000 shares, the short-interest ratio is presently 2.5 days.

Analysts Set New Price Targets

CMPX has been the subject of a number of analyst reports. Leerink Partnrs downgraded shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Finally, D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Compass Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $11.80.

Compass Therapeutics Stock Up 4.0 %

NASDAQ CMPX traded up $0.10 on Friday, hitting $2.60. 1,402,133 shares of the company's stock were exchanged, compared to its average volume of 1,506,824. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $2.70. The stock has a 50-day moving average of $1.62 and a 200-day moving average of $1.50.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Equities analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in CMPX. Geode Capital Management LLC increased its position in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock worth $4,251,000 after purchasing an additional 19,095 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after buying an additional 356,352 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company's stock valued at $284,000 after acquiring an additional 31,433 shares during the last quarter. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.